Promises
2 promises
Promise Tracker
0 delivered, 0 close, 2 missed.
View Promises →Everest Kanto Cylinder Limited — Q3 FY26
Everest Kanto delivered a strong Q3 FY26 with consolidated EBITDA up 48% YoY to ₹59.2 crore and PAT surging 98.9% to ₹35.7 crore.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Everest Kanto delivered a strong Q3 FY26 with consolidated EBITDA up 48% YoY to ₹59.2 crore and PAT surging 98.9% to ₹35.7 crore. Margin expansion of 534 bps to 16.2% was driven by a favorable product mix shift toward higher-margin segments (defense, semiconductor, CNG CV cylinders) and cost discipline. Standalone EBITDA margin reached 23.1%. Management guided for sustainable 15-17% consolidated margins and 15-20% revenue growth in FY27. Key growth drivers include the Mundra greenfield facility (one line operational, two more coming), Egypt plant (commissioning by May '26, ₹50-60 crore revenue potential), and a US capacity expansion backed by customer contracts (₹100 crore incremental revenue by FY28). UAE operations remain subdued but are expected to break even in FY27. Risk: UAE recovery may be slower than anticipated, and product mix volatility could pressure margins.
Promises0 met · 2 missedRisks3 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
3 risks
Risk Intelligence
UAE business recovery may be slower than expected
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Standalone EBITDA Margin
23.1%
+820 bps YoY
Standalone margin expanded from 14.9% in Q3 FY25 to 23.1% in Q3 FY26.
Capacity Utilization
70-75%
flat
Overall capacity utilization across plants is around 70-75%.
US Order Book
$50-75M
flat
US order book is approximately $50-75 million with execution over ~2 years.
Mundra Capacity Addition
15%
+15%
Mundra facility will increase overall capacity by ~15% once all lines are operational.
What Changed vs Last Quarter
NEW
Consolidated EBITDA margin sustainable at 15-17%
Management expects consolidated EBITDA margins to remain in the 15-17% range going forward, supported by product mix and cost discipline.
NEW
Revenue growth target of 15-20% for FY27
The company targets 15-20% revenue growth in FY27, driven by new capacities and demand recovery.
NEW
Egypt facility to commence operations by May 2026
The Egypt plant is expected to start production by May 2026, with first-year revenue potential of ₹50-60 crore.
NEW
US capacity expansion to add ₹100 crore revenue by FY28
A $5.5 million capex in the US subsidiary, backed by customer contracts, is expected to generate incremental revenue of ~₹100 crore by FY28.
DROPPED
EBITDA margin guidance of 12-14% for FY26
Management expects full-year EBITDA margins to be in the range of 12-14%.
DROPPED
Egypt plant trial production by January 2026
The Egypt facility is expected to begin trial production by January 2026.
DROPPED
Mundra plant commercialization by March 2026
The Mundra plant is expected to be commercialized by March 2026.
DROPPED
Revenue target of ₹900-2,000 crore for standalone
Management indicated a revenue target range for standalone business, though exact figure was unclear.
NEW RISK
UAE business recovery may be slower than expected
UAE operations remain subdued; management expects break-even only at 10% higher revenue, with no clear timeline for recovery.
NEW RISK
Product mix volatility could impact margins
Margins are influenced by product mix each quarter; a shift toward lower-margin products could compress profitability.
NEW RISK
GST case outcome uncertain
The company has an ongoing GST case in India with no update or timeline for resolution, posing potential financial risk.
RISK GONE
GST litigation uncertainty
The company has received GST demands and is awaiting government response; outcome and timeline are uncertain.
RISK GONE
Forex penalty recurrence
A ₹11 crore penalty was incurred for shortfall in net foreign exchange earnings; similar penalties may arise in future assessments.
RISK GONE
Margin pressure from product mix
Gross margins declined due to lower volumes in high-margin products; mix shift could continue to pressure margins.
🤫 Topics management stopped discussing
Mentioned in Q1 FY26, Q2 FY26
The Egypt facility is expected to begin trial production by January 2026.
Fast read
Guidance and risk preview
Management expects consolidated EBITDA margins to remain in the 15-17% range going forward, supported by product mix and cost discipline.
UAE operations remain subdued; management expects break-even only at 10% higher revenue, with no clear timeline for recovery.
View Risks →